<verdict>MOSTLY REALISTIC</verdict>
<score>8</score>
<reasoning>
**Rolls.** All six action rolls and all five threat rolls are applied correctly against their stated thresholds.
- A1: 85 vs 50, success.
- A6: 16 vs 15, marginal success.
- T1: 34 vs 35, materialises.
- T2: 34 vs 30, does not materialise.

The probabilities are broadly well calibrated. The tweaks to the adversary's suggested likelihoods are reasoned, such as T5 raised because of xAI's pattern and T3 lowered because the dedupe now runs before labelling.

**Materialised threats.** These are woven in proportionately. Action 1 succeeds, so the successor rule returns via Vote A. T1 still bites: Vote B is tabled, the 7-day promise is broken, and the "changed the test" frame appears. SecureBio declining developer-funded hours is a highly plausible independence move. It produces a believable fourth bio slip to December. The pacing on institutions is good: Michigan audits slip to January, Colorado's procurement office forces re-pricing, and OpenAI files an unequal-treatment question.

**Problems.** T4 was lowered to 35% explicitly because its harms were "separable and not all would land together." All four harms then landed anyway: Colorado no-cost ruling, Michigan slip, observer narrowing, and the OpenAI protest question. The exogenous FinCEN alert citing the player's M3AAWG dataset is plausible but mildly convenient, and it is scored as a positive narrative. Action 6 passed by a single point yet delivered an almost fully favourable package: 7-day detector rollout, 4 of 5 laggards opting in, a $1.2M fraud stopped, and AI2 confirmation. Only the closed-model baseline was held back.
</reasoning>
<issues>
- **T4 rationale contradicted.** P was cut to 35% on the grounds that harms were separable. Then every sub-harm materialised simultaneously, when the simulator should have picked a subset or kept P at 45%.
- **Marginal A6 success (16 vs 15) resolved too generously.** Nearly every sub-item succeeded. A one-point margin should have produced more partial outcomes, such as a slower rollout or fewer mirror opt-ins.
- **Convenient exogenous event.** FinCEN explicitly citing the player's dataset is a favourable detail. A generic alert on voice-clone fraud would have been the more neutral choice.
- **T2 partly leaked in despite not materialising.** Privacy restricted reuse to about 1,900 opted-in rows. This is defensible as the baseline effect, but it blurs the line.
- **Date error.** The world state lists a "Q1 2026 re-read"; it should be Q1 2030.
- **Unexplained new fact.** Alt-protein "5 licensees" appears without prior grounding.
- **Scorecard overclaims.** It says the "governance gap closed" while the clinical vote remains tabled and bio is unverified.
- **Thin competitor-lab coverage.** There are no GDM or OpenAI capability or release developments in the exogenous events despite an active frontier.
</issues>
<feedback_for_simulator>
- When you lower a multi-harm threat's probability because its harms are separable, and it then materialises, apply only a subset of harms in proportion to the margin.
- Scale success breadth to the roll margin. A 1-point pass on a bundled action should leave several sub-items partial or delayed.
- Keep exogenous events neutral. Avoid having regulators spontaneously cite the player's own artifacts unless there is an established channel.
- Fix date and consistency slips (Q1 2030, not 2026), and include at least one competitor-lab or capability event in the exogenous set next month.
</feedback_for_simulator>
